CERo Therapeutics Holdings, Inc. (CEROW)
USD 0.01
(-23.73%)
USD 0.01
(-23.73%)
| Breakdown | 2023 | 2022 | 2021 |
|---|---|---|---|
| Revenue | - | - | - |
| Cost of Revenue | - | - | - |
| Gross Profit | - | - | - |
| Operating Expenses | 2.93 Million | 2.9 Million | 332.02 Thousand |
| Selling, General and Administrative Expenses | 2.89 Million | 2.84 Million | 251.7 Thousand |
| Research and Development Expenses | - | 9.84 Million | 9.13 Million |
| Other Expenses | 40.05 Thousand | -64.05 Thousand | -80.32 Thousand |
| Cost and Expenses | 2.93 Million | 2.9 Million | 332.03 Thousand |
| Operating Income | -2.93 Million | -2.9 Million | -332.03 Thousand |
| Interest Expense | - | - | - |
| Income Tax Expense | 94.81 Thousand | 599.15 Thousand | -16.86 Thousand |
| Earnings before Tax | -2.44 Million | -68.57 Thousand | -332.41 Thousand |
| Net Income | -2536.23 | -667.73 Thousand | -315.54 Thousand |
| Earnings Per Share Basic | -0.39 | -0.10 | -0.01 |
| Earnings Per Share Diluted | -0.39 | -0.10 | -0.01 |
| Weighted Average Shares Outstanding | 6.52 Million | 6.76 Million | 22.98 Million |
| Weighted Average Shares Outstanding (Diluted) | 6.52 Million | 6.76 Million | 22.98 Million |
| Gross Margin | - | - | - |
| EBIT Margin | - | - | - |
| Profit Margin | - | - | - |
| EBITDA | -2.44 Million | -68.57 Thousand | -332.03 Thousand |
| Earnings Before Tax Margin | - | - | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | 293.25 Thousand | 288.16 Thousand | - | - | - | - |
| Gross Profit | -293.25 Thousand | -288.16 Thousand | - | - | - | - |
| Operating Expenses | 4.85 Million | 4.26 Million | 2.93 Million | 369.33 Thousand | 429.8 Thousand | 1.54 Million |
| Selling, General and Administrative Expenses | 2.43 Million | 2.88 Million | - | 374.58 Thousand | 430.9 Thousand | 1.52 Million |
| Research and Development Expenses | 2.42 Million | 1.38 Million | - | - | - | 1.19 Million |
| Other Expenses | -630.77 Thousand | - | -40.05 Thousand | 5250.00 | 1100.00 | -22.7 Thousand |
| Cost and Expenses | 5.14 Million | 4.55 Million | 2.93 Million | 369.33 Thousand | 429.8 Thousand | 1.54 Million |
| Operating Income | -5.14 Million | -4.55 Million | -2.93 Million | -369.34 Thousand | -429.8 Thousand | -1.54 Million |
| Interest Expense | 16.97 Thousand | 9629.00 | - | - | - | - |
| Income Tax Expense | -2.00 | -1.00 | 94.81 Thousand | 24.41 Thousand | 25.75 Thousand | 44.65 Thousand |
| Earnings before Tax | -2.44 Million | -2.29 Million | -2.44 Million | -258.35 Thousand | -308.27 Thousand | -1.39 Million |
| Net Income | -2.44 Million | -2.29 Million | -2.53 Million | -282.76 Thousand | -334.02 Thousand | -1.42 Million |
| Earnings Per Share Basic | -0.15 | -0.16 | - | -0.05 | -0.05 | -0.21 |
| Earnings Per Share Diluted | -0.15 | -0.16 | - | -0.05 | -0.05 | -0.21 |
| Weighted Average Shares Outstanding | 16.19 Million | 14.7 Million | 6.52 Million | 6.24 Million | 6.33 Million | 6.76 Million |
| Weighted Average Shares Outstanding (Diluted) | 16.19 Million | 14.7 Million | 6.52 Million | 6.24 Million | 6.33 Million | 6.76 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -4.85 Million | -4.26 Million | - | -369.34 Thousand | -429.8 Thousand | -1.54 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
OMAB
LEGIF
INT
4346
FRW
YOOIF